Navigation Links
OHSU Knight Cancer Institute researcher wins prestigious early-career award

PORTLAND, Ore. Jeffrey Tyner, Ph.D., assistant professor of Cell, Developmental & Cancer Biology for Oregon Health & Science University (OHSU) and a researcher with OHSU's Knight Cancer Institute, has won a distinguished award from the American Association for the Advancement of Science (AAAS) for the development of a research program that more rapidly identifies the mutations driving a patient's cancer and accelerates development of precision treatments. Tyner shares the AAAS Martin and Rose Wachtel Cancer Research Award, which honors early-career cancer researchers, with Li Ma, Ph.D., of MD Anderson Cancer Center at the University of Texas.

Tyner and Ma's award entry essays were published in the July 2 edition of Science Translational Medicine. Both will deliver public lectures on their research July 7.

Tyner's work is distinguished by analyzing data on genetic mutations in patients' cancer cells, derived through deep genomic sequencing, and simultaneously assessing the manner by which tumor cells with those mutations respond to a variety of gene-targeted drugs. This approach more accurately determines which aberrations are most lethal and how they can be targeted with a precision treatment. It also allows for a better understanding of the biology of each patient's disease and, in some cases, identified new subtypes of the disease.

"Full delivery of the promise of genetically driven medicine will require that we make the leap from knowledge of cancer genetic events and translate this information into new and personalized therapeutic regimens for patients," Tyner wrote in his award essay.

Tyner's peer-reviewed studies in Cancer Cell in 2012 and the New England Journal of Medicine last year demonstrate the benefits of this research approach. The latter study pinpointed a cause of two types of leukemia and demonstrated the possibility that these diseases could be treated with existing FDA-approved drugs. As a result, a clinical trial to test ruxolitinib in patients with chronic neutrophilic leukemia (CNL) that is driven by mutations in a gene called colony stimulating factor 3 receptor (CSF3R) is soon to open.

"Jeffrey Tyner's work is making a significant contribution to the advancement of personalized cancer medicine. His approach makes it possible to achieve new discoveries in months that used to take decades," said Brian Druker, M.D., director of the Knight Cancer Institute. "It is gratifying to see his contributions recognized with an AAAS Martin and Rose Wachtel Cancer Research Award."

Tyner's methodology also forms the backbone of Beat AML, a pioneering collaboration launched in 2013 between The Leukemia & Lymphoma Society (LLS) and the Knight Cancer Institute to vastly accelerate development of treatments for patients with acute myeloid leukemia (AML). AML is a particularly devastating blood cancer with less than 25 percent of newly diagnosed patients surviving beyond five years. It causes more than 10,000 deaths a year in the United States, and treatment options largely have not changed in the past 30 years.

Beat AML creates a profile of the possible genetic drivers of AML by conducting a deep genomic sequencing analysis of participating AML patients' samples. As information from the samples is analyzed by the Knight Cancer Institute's bioinformatics team to determine potentially relevant mutations, researchers simultaneously test the response of patients' leukemia cells to different drugs and combinations of drugs. This dual process on patient samples better equips scientists to confirm that they have correctly identified a genetic driver of the disease. It not only speeds progress in understanding AML, but more efficiently determines ways to stop the disease and block potential recurrence.

Tyner said his lab will likely deploy a similar model for drug development for other types of cancer in the future. "It's an honor to have this work recognized by the American Association for the Advancement of Science, and it is another strong incentive to perform research that will improve therapeutic options and clinical outcomes for patients."

Tyner was named an assistant professor in the OHSU School of Medicine in 2012 following a postdoctoral fellowship in Brian Druker's laboratory. A native of West Lafayette, Indiana, Tyner earned his Ph.D. from Washington University's School of Medicine in St. Louis, Missouri, and his B.A. from Grinnell College in Grinnell, Iowa.


Contact: Elisa Williams
Oregon Health & Science University

Related biology news :

1. Chinese herbal extract may help kill off pancreatic cancer cells
2. The inhibition of a protein opens the door to the treatment of pancreatic cancer
3. Is the next new cancer drug already in your medicine cabinet?
4. No link between fertility drugs and breast, ovarian and uterine cancers
5. A single gene separates aggressive and non-aggressive lymphatic system cancer
6. First positive results toward a therapeutic vaccine against brain cancer
7. Synthetic triterpenoids show promise in preventing colitis-associated colon cancer
8. CNIO researcher Ana Losada revises the role of cohesin in cancer
9. Pew and the Stewart Trust launch scholars program targeting cancer
10. Damon Runyon Cancer Research foundation awards $4M to 10 top young clinical investigators
11. Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors
Post Your Comments:
Related Image:
OHSU Knight Cancer Institute researcher wins prestigious early-career award
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
(Date:11/24/2015)... ALBANY, New York , November 24, 2015 /PRNewswire/ ... According to a recent market research report released by ... is projected to expand at a CAGR of 17.5% ... titled "Non-invasive Prenatal Testing Market - Global Industry Analysis, ... 2022", estimates the global non-invasive prenatal testing market to ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial processes, ... for in-line sensors can represent a weak spot where leaking process media is ... retractable sensor housings , which are designed to tolerate extreme process conditions. They ...
Breaking Biology Technology: